A Study of APG-2575 in Patients with Mild-to-moderate Systemic Lupus Erythematosus.

Launched by ASCENTAGE PHARMA GROUP INC. · Dec 13, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called APG-2575 for patients with mild-to-moderate systemic lupus erythematosus (SLE), a condition that causes the immune system to mistakenly attack healthy tissues. The goal of the study is to find out how safe this treatment is, how well it works, and how it moves through the body. The trial is currently looking for female participants aged 18 to 75 who have been diagnosed with SLE for at least six months and are on stable medication for at least 28 days.

If you join the trial, you will receive the study medication in multiple doses, and your health will be closely monitored throughout the process. It's important to note that this study is not for individuals with severe SLE or other significant autoimmune diseases. Participating in this trial could contribute to understanding new treatment options for SLE, and help improve care for others living with this condition.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of systemic lupus erythematosus for at least 6 months.
• • 2. On stable treatment for systemic lupus erythematosus before first dose at least 28 days.
• • 3. SLEDIA-2000 score: 4-12
• • 4.Other than systemic lupus erythematosus, subject should be in general good health.
• Exclusion Criteria:
• • 1. Severe systemic lupus erythematosus.
• • 2. Significant autoimmune disease other than lupus.
• • 3. Significant, uncontrolled or unstable disease in any organ.